中国临床药理学杂志2023，Vol.39Issue(23)：3479-3481,3.DOI:10.13699/j.cnki.1001-6821.2023.23.029
银屑病患者应用白细胞介素-17A抑制药发生结核性腹膜炎的病例分析
Case report of tuberculous peritonitis in a patient with psoriasis using interleukin-17 A inhibitors
摘要
Abstract
Secukinumab,a novel interleukin-17A(IL-17A)inhibitor biologic agent,is approved for treating psoriasis,ankylosing spondylitis,and related conditions.Its downstream effects on inflammatory pathways have minimal impact on infectious diseases,making it relatively safe for clinical use.To our knowledge,there are currently no reports of secukinumab activating latent tuberculosis infections into active tuberculosis.However,this report presents a case of tuberculous peritonitis that developed after 11 months of secukinumab therapy for psoriasis,emphasizing the importance of monitoring potential adverse events associated with its use,particularly in patients with underlying risk factors for latent tuberculosis infections.关键词
司库奇尤/白细胞介素-17A抑制药/结核分枝杆菌/肺外结核/银屑病Key words
secukinumab/interleukin-17 A inhibitor/mycobacterium tuberculosis/extrapulmonary tuberculosis/psoriasis分类
医药卫生引用本文复制引用
董晶,马序竹,王小辉,林明贵..银屑病患者应用白细胞介素-17A抑制药发生结核性腹膜炎的病例分析[J].中国临床药理学杂志,2023,39(23):3479-3481,3.基金项目
北京市属医院科研培育基金资助项目(PX2020042) （PX2020042）
